Concepts (334)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 18 | 2025 | 621 | 5.930 |
Why?
|
| Dermatology | 9 | 2025 | 46 | 5.160 |
Why?
|
| Skin | 16 | 2025 | 576 | 3.430 |
Why?
|
| Skin Diseases | 8 | 2025 | 174 | 3.330 |
Why?
|
| Photochemotherapy | 10 | 2024 | 100 | 3.110 |
Why?
|
| Acne Vulgaris | 5 | 2024 | 33 | 2.700 |
Why?
|
| Education, Medical | 4 | 2024 | 228 | 2.320 |
Why?
|
| Keratosis, Actinic | 4 | 2024 | 13 | 1.900 |
Why?
|
| Melanoma | 6 | 2024 | 495 | 1.840 |
Why?
|
| Photosensitizing Agents | 9 | 2024 | 52 | 1.680 |
Why?
|
| Skin Diseases, Genetic | 2 | 2023 | 7 | 1.500 |
Why?
|
| Artificial Intelligence | 3 | 2025 | 395 | 1.450 |
Why?
|
| Nevus, Pigmented | 4 | 2023 | 58 | 1.440 |
Why?
|
| Skin Aging | 4 | 2025 | 31 | 1.380 |
Why?
|
| Internship and Residency | 4 | 2021 | 1089 | 1.370 |
Why?
|
| Dermatitis, Atopic | 3 | 2022 | 65 | 1.360 |
Why?
|
| Mohs Surgery | 4 | 2024 | 27 | 1.360 |
Why?
|
| Pigmentation Disorders | 2 | 2019 | 13 | 1.210 |
Why?
|
| Nevus | 3 | 2023 | 18 | 1.190 |
Why?
|
| Scalp Dermatoses | 2 | 2019 | 10 | 1.150 |
Why?
|
| Humans | 74 | 2025 | 93609 | 1.100 |
Why?
|
| Erythema | 4 | 2023 | 31 | 1.000 |
Why?
|
| Laser Therapy | 6 | 2024 | 151 | 0.970 |
Why?
|
| Phototherapy | 2 | 2016 | 34 | 0.960 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 1077 | 0.930 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 381 | 0.920 |
Why?
|
| Sunscreening Agents | 1 | 2024 | 10 | 0.850 |
Why?
|
| Exosomes | 1 | 2025 | 60 | 0.840 |
Why?
|
| Melanosis | 1 | 2024 | 6 | 0.830 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 13 | 0.790 |
Why?
|
| Interleukin-4 | 2 | 2021 | 135 | 0.780 |
Why?
|
| Rejuvenation | 3 | 2024 | 20 | 0.770 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2023 | 236 | 0.760 |
Why?
|
| Aminolevulinic Acid | 3 | 2019 | 22 | 0.750 |
Why?
|
| Vitamin A | 1 | 2022 | 27 | 0.750 |
Why?
|
| Rhinitis, Allergic | 1 | 2022 | 52 | 0.720 |
Why?
|
| Mouth Mucosa | 2 | 2019 | 71 | 0.720 |
Why?
|
| Urticaria | 1 | 2022 | 15 | 0.710 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2019 | 8 | 0.700 |
Why?
|
| Exanthema | 1 | 2022 | 39 | 0.690 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.660 |
Why?
|
| Teaching Materials | 1 | 2020 | 15 | 0.650 |
Why?
|
| Dermatologists | 1 | 2020 | 2 | 0.640 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2020 | 7 | 0.640 |
Why?
|
| Drug Eruptions | 2 | 2021 | 34 | 0.640 |
Why?
|
| Ear Neoplasms | 1 | 2020 | 14 | 0.640 |
Why?
|
| Mucositis | 1 | 2020 | 18 | 0.640 |
Why?
|
| Certification | 1 | 2020 | 60 | 0.640 |
Why?
|
| Margins of Excision | 1 | 2020 | 45 | 0.630 |
Why?
|
| Private Practice | 1 | 2020 | 12 | 0.630 |
Why?
|
| Coronavirus | 1 | 2020 | 20 | 0.620 |
Why?
|
| Career Mobility | 1 | 2020 | 37 | 0.620 |
Why?
|
| Hyperpigmentation | 2 | 2017 | 7 | 0.620 |
Why?
|
| Low-Level Light Therapy | 1 | 2019 | 15 | 0.610 |
Why?
|
| SEER Program | 4 | 2021 | 235 | 0.610 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2019 | 4 | 0.610 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 559 | 0.600 |
Why?
|
| Herpes Simplex | 1 | 2020 | 79 | 0.600 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2019 | 24 | 0.600 |
Why?
|
| Silicone Gels | 1 | 2019 | 3 | 0.600 |
Why?
|
| Bacteremia | 1 | 2020 | 107 | 0.590 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 17 | 0.590 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2301 | 0.580 |
Why?
|
| MicroRNAs | 2 | 2021 | 580 | 0.570 |
Why?
|
| Eyelids | 2 | 2016 | 24 | 0.570 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2018 | 6 | 0.560 |
Why?
|
| Tomography, Optical Coherence | 5 | 2025 | 131 | 0.550 |
Why?
|
| United States | 8 | 2025 | 7642 | 0.550 |
Why?
|
| Pandemics | 2 | 2023 | 875 | 0.540 |
Why?
|
| Skin Diseases, Infectious | 1 | 2017 | 8 | 0.530 |
Why?
|
| Pain | 2 | 2019 | 415 | 0.530 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 202 | 0.500 |
Why?
|
| Licensure, Medical | 3 | 2021 | 20 | 0.500 |
Why?
|
| Diagnosis, Differential | 5 | 2023 | 1546 | 0.490 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1103 | 0.480 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 77 | 0.480 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 990 | 0.450 |
Why?
|
| Aspergillosis | 1 | 2015 | 39 | 0.450 |
Why?
|
| Pityriasis Rubra Pilaris | 2 | 2019 | 3 | 0.450 |
Why?
|
| Infant | 4 | 2023 | 3220 | 0.450 |
Why?
|
| Blepharoplasty | 1 | 2015 | 8 | 0.450 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 57 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.440 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.440 |
Why?
|
| Biological Products | 1 | 2017 | 178 | 0.440 |
Why?
|
| Patient Compliance | 1 | 2016 | 237 | 0.430 |
Why?
|
| Asthma | 1 | 2022 | 1039 | 0.420 |
Why?
|
| Aged | 13 | 2025 | 20469 | 0.420 |
Why?
|
| Photoacoustic Techniques | 2 | 2024 | 7 | 0.420 |
Why?
|
| Condylomata Acuminata | 1 | 2014 | 11 | 0.420 |
Why?
|
| Male | 23 | 2025 | 44580 | 0.410 |
Why?
|
| Sweet Syndrome | 2 | 2014 | 6 | 0.410 |
Why?
|
| Female | 25 | 2025 | 48778 | 0.400 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 45 | 0.400 |
Why?
|
| Skin Pigmentation | 3 | 2024 | 36 | 0.400 |
Why?
|
| Middle Aged | 15 | 2025 | 27621 | 0.380 |
Why?
|
| Epidermis | 3 | 2024 | 103 | 0.380 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2479 | 0.340 |
Why?
|
| Antiviral Agents | 1 | 2014 | 364 | 0.340 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7072 | 0.330 |
Why?
|
| Esthetics | 3 | 2021 | 50 | 0.320 |
Why?
|
| Treatment Outcome | 7 | 2024 | 9109 | 0.310 |
Why?
|
| Cicatrix | 2 | 2024 | 74 | 0.310 |
Why?
|
| Retrospective Studies | 5 | 2022 | 10185 | 0.300 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 8 | 0.300 |
Why?
|
| Dermis | 1 | 2009 | 30 | 0.300 |
Why?
|
| Heart Transplantation | 1 | 2015 | 814 | 0.290 |
Why?
|
| Ultraviolet Therapy | 1 | 2009 | 17 | 0.290 |
Why?
|
| Sarcoidosis | 2 | 2020 | 92 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2019 | 71 | 0.290 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 226 | 0.290 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2024 | 63 | 0.270 |
Why?
|
| Color | 2 | 2019 | 80 | 0.260 |
Why?
|
| Age Factors | 3 | 2025 | 1907 | 0.260 |
Why?
|
| Curriculum | 2 | 2021 | 594 | 0.240 |
Why?
|
| Administration, Topical | 2 | 2018 | 80 | 0.240 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1919 | 0.240 |
Why?
|
| Rosacea | 1 | 2025 | 1 | 0.230 |
Why?
|
| Survival Rate | 2 | 2020 | 1951 | 0.230 |
Why?
|
| Cosmetic Techniques | 2 | 2016 | 28 | 0.230 |
Why?
|
| Adult | 12 | 2025 | 27947 | 0.230 |
Why?
|
| Edema | 2 | 2023 | 70 | 0.230 |
Why?
|
| Migraine Disorders | 1 | 2025 | 41 | 0.220 |
Why?
|
| Biomarkers | 3 | 2021 | 1913 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 139 | 0.210 |
Why?
|
| Striae Distensae | 1 | 2024 | 1 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 835 | 0.210 |
Why?
|
| Administration, Cutaneous | 1 | 2024 | 61 | 0.210 |
Why?
|
| Dermatomycoses | 1 | 2023 | 10 | 0.200 |
Why?
|
| Patient Care | 1 | 2024 | 97 | 0.190 |
Why?
|
| Child | 5 | 2022 | 7361 | 0.190 |
Why?
|
| Video Recording | 1 | 2024 | 212 | 0.190 |
Why?
|
| Retinoids | 1 | 2022 | 18 | 0.190 |
Why?
|
| Biopsy | 3 | 2023 | 1177 | 0.190 |
Why?
|
| Varicose Ulcer | 1 | 2022 | 6 | 0.190 |
Why?
|
| Health Literacy | 1 | 2024 | 85 | 0.190 |
Why?
|
| Purpura | 2 | 2000 | 13 | 0.190 |
Why?
|
| Phenols | 1 | 2022 | 41 | 0.190 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1723 | 0.180 |
Why?
|
| Hidradenitis | 1 | 2021 | 2 | 0.180 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2021 | 13 | 0.180 |
Why?
|
| Incidence | 2 | 2023 | 1702 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 69 | 0.170 |
Why?
|
| Ultrasonography | 1 | 2024 | 702 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 457 | 0.170 |
Why?
|
| Insulin Resistance | 2 | 2021 | 380 | 0.170 |
Why?
|
| Bronchogenic Cyst | 1 | 2021 | 5 | 0.170 |
Why?
|
| Dermoid Cyst | 1 | 2021 | 15 | 0.170 |
Why?
|
| Up-Regulation | 2 | 2021 | 729 | 0.170 |
Why?
|
| Dermoscopy | 1 | 2020 | 7 | 0.170 |
Why?
|
| Sex Factors | 2 | 2025 | 1104 | 0.160 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2020 | 5 | 0.160 |
Why?
|
| Ear, External | 1 | 2020 | 24 | 0.160 |
Why?
|
| Staphylococcus epidermidis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2020 | 2 | 0.160 |
Why?
|
| Accreditation | 1 | 2020 | 74 | 0.160 |
Why?
|
| Personnel Selection | 1 | 2020 | 63 | 0.160 |
Why?
|
| Necrosis | 3 | 2015 | 204 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1584 | 0.150 |
Why?
|
| Mannose-Binding Lectins | 1 | 2019 | 7 | 0.150 |
Why?
|
| Tattooing | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mutagens | 1 | 2019 | 29 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 270 | 0.150 |
Why?
|
| Simplexvirus | 1 | 2020 | 66 | 0.150 |
Why?
|
| Panuveitis | 1 | 2019 | 4 | 0.150 |
Why?
|
| Mastocytoma, Skin | 1 | 2019 | 1 | 0.150 |
Why?
|
| Corneal Ulcer | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mastocytoma | 1 | 2019 | 4 | 0.150 |
Why?
|
| Scleritis | 1 | 2019 | 4 | 0.150 |
Why?
|
| Lupus Vulgaris | 1 | 2019 | 4 | 0.150 |
Why?
|
| Protective Factors | 1 | 2019 | 28 | 0.150 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2019 | 5 | 0.150 |
Why?
|
| S100 Proteins | 1 | 2019 | 51 | 0.150 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 7 | 0.150 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 37 | 0.150 |
Why?
|
| Cultural Diversity | 1 | 2020 | 63 | 0.150 |
Why?
|
| Paraproteinemias | 1 | 2019 | 19 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2019 | 71 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2020 | 363 | 0.150 |
Why?
|
| Arthralgia | 1 | 2019 | 41 | 0.150 |
Why?
|
| Antigen-Antibody Complex | 1 | 2019 | 88 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 876 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 455 | 0.150 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 433 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 149 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2000 | 118 | 0.140 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 83 | 0.140 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 30 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 538 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 244 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 321 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 9 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2019 | 476 | 0.130 |
Why?
|
| Keratinocytes | 1 | 2018 | 146 | 0.130 |
Why?
|
| Wound Healing | 2 | 2019 | 373 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 505 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 180 | 0.130 |
Why?
|
| Telemedicine | 1 | 2020 | 226 | 0.130 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1997 | 2 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 603 | 0.130 |
Why?
|
| Motivation | 1 | 2020 | 310 | 0.130 |
Why?
|
| Neutrophils | 3 | 2021 | 324 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 889 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 350 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1865 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 183 | 0.120 |
Why?
|
| Hospitalization | 1 | 2022 | 938 | 0.120 |
Why?
|
| Nocardia Infections | 1 | 2016 | 4 | 0.120 |
Why?
|
| Onychomycosis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2016 | 1 | 0.120 |
Why?
|
| Telangiectasis | 1 | 2016 | 8 | 0.120 |
Why?
|
| Logistic Models | 2 | 2019 | 1245 | 0.120 |
Why?
|
| Doxycycline | 1 | 2016 | 37 | 0.120 |
Why?
|
| Hirsutism | 1 | 2016 | 53 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2804 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2020 | 434 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 427 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2021 | 821 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2017 | 524 | 0.120 |
Why?
|
| Young Adult | 2 | 2025 | 6936 | 0.110 |
Why?
|
| Cosmetics | 1 | 2015 | 7 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 826 | 0.110 |
Why?
|
| Life Change Events | 1 | 2015 | 46 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1790 | 0.110 |
Why?
|
| Cellulitis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 21 | 0.100 |
Why?
|
| Caustics | 1 | 2014 | 4 | 0.100 |
Why?
|
| Cryotherapy | 1 | 2014 | 30 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2493 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 122 | 0.100 |
Why?
|
| Prognosis | 1 | 2021 | 3915 | 0.100 |
Why?
|
| Animals | 7 | 2024 | 28047 | 0.100 |
Why?
|
| Child Development | 1 | 2015 | 166 | 0.100 |
Why?
|
| Muir-Torre Syndrome | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adolescent | 4 | 2025 | 9611 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 125 | 0.090 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 26 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 5914 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 647 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1050 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2014 | 248 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 283 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 690 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1661 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 577 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 2444 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2543 | 0.080 |
Why?
|
| Adenoma | 1 | 2012 | 258 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2021 | 3500 | 0.080 |
Why?
|
| HIV Infections | 1 | 2019 | 955 | 0.080 |
Why?
|
| Mice | 2 | 2021 | 12239 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 1866 | 0.070 |
Why?
|
| Rabbits | 3 | 2000 | 613 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 34 | 0.070 |
Why?
|
| Obesity | 2 | 2015 | 1019 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2021 | 523 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 755 | 0.070 |
Why?
|
| Dermatofibrosarcoma | 1 | 2008 | 13 | 0.070 |
Why?
|
| Porphyrins | 2 | 1998 | 37 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 767 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 873 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 55 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 1719 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2024 | 191 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2023 | 25 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1932 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 38 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 193 | 0.050 |
Why?
|
| Burns | 1 | 2024 | 149 | 0.040 |
Why?
|
| Hair Removal | 1 | 2002 | 14 | 0.040 |
Why?
|
| Sweat Glands | 1 | 2021 | 6 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2002 | 159 | 0.040 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 41 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2021 | 77 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2021 | 53 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 1243 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 1322 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 917 | 0.040 |
Why?
|
| Leg Ulcer | 1 | 2001 | 7 | 0.040 |
Why?
|
| Cytarabine | 1 | 2021 | 216 | 0.040 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2001 | 20 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 278 | 0.040 |
Why?
|
| Ischemia | 1 | 2022 | 253 | 0.040 |
Why?
|
| Pruritus | 1 | 2000 | 30 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 241 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2000 | 92 | 0.040 |
Why?
|
| Software | 1 | 2024 | 671 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2001 | 191 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 504 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 1262 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2018 | 41 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 4042 | 0.030 |
Why?
|
| Maximum Allowable Concentration | 1 | 1997 | 2 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1449 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 1997 | 19 | 0.030 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1997 | 41 | 0.030 |
Why?
|
| Fluorescence | 1 | 1997 | 100 | 0.030 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Light | 1 | 1997 | 287 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1191 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1956 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 4563 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 759 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 36 | 0.030 |
Why?
|
| Time Factors | 3 | 2002 | 5406 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 28 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1783 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2592 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 170 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 812 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1007 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1166 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1989 | 36 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1989 | 135 | 0.020 |
Why?
|
| Furocoumarins | 1 | 2007 | 2 | 0.020 |
Why?
|
| New Hampshire | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 19 | 0.020 |
Why?
|
| Diet | 1 | 1989 | 461 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 192 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 47 | 0.010 |
Why?
|
| Skin, Artificial | 1 | 2001 | 7 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3833 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 95 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 1014 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 290 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 88 | 0.010 |
Why?
|
| Iontophoresis | 1 | 1997 | 4 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 256 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1769 | 0.010 |
Why?
|
| Plant Oils | 1 | 1989 | 8 | 0.000 |
Why?
|
| Occupations | 1 | 1989 | 24 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1989 | 356 | 0.000 |
Why?
|
| Smoking | 1 | 1989 | 648 | 0.000 |
Why?
|